Additional support also comes from clinical evidence that CaV1 blockers for hypertension treatment, e.g., 1,4-dihydropyridines (DHPs) appear to reduce the risk of PD (Pasternak et al., 2012; Ritz et al., 2009). This evidence concerns the gene CAV1 and Parkinson disease.